Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 108Breast Neoplasms 72Carcinoma, Non-Small-Cell Lung 38Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Esophageal Squamous Cell Carcinoma 14Neoplasms 12Head and Neck Neoplasms 11Lung Neoplasms 10Stomach Neoplasms 9Gallbladder Neoplasms 8Cholangiocarcinoma 8Adenocarcinoma 8Melanoma 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Sarcoma 6Ovarian Neoplasms 5Inflammatory Breast Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Pancreatic Adenocarcinoma 4Carcinoma, Ductal, Breast 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Tongue Neoplasms 3Thymoma 3Pancreatic Diseases 3Nasopharyngeal Carcinoma 3

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced or Metastatic Gastric Adenocarcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡